spacer
home > ebr > summer 2018 > targeted treatment
PUBLICATIONS
European Biopharmaceutical Review

Targeted Treatment

The goal of therapy is to treat infected/diseased tissues and leave healthy tissues unharmed. Unfortunately, therapeutics often have side effects due to off-target interactions, as is evident with chemotherapeutics used to treat cancer. In conditions with high mortality rates (such as cancer), patients are often willing to accept side effects to maximise the effect of treatment on the cancer. However, these off-target effects could be reduced if the drug can be more effectively delivered to the diseased tissues. Examples of this targeting have been achieved through the use of antibody-drug conjugates (ADCs) (see Figure 1).

With the obvious benefits of this targeting approach, it may be surprising to learn that, to date, only four ADCs have received FDA approval – the first of which (Gemtuzumab ozogamicin) was approved in 2001 for the treatment of acute myelognous leukaemia. Several factors have limited ADC progress, which largely revolve around issues with the antibody component. Firstly, antibodies themselves are part of the immune system, and even minimised fragments used in more recent ADC developments are still potentially immunogenic. This can lead to immune-related side effects. Another issue with ADCs is their relatively poor tissue penetration in solid tumours, although this is less problematic for smaller, recombinant antibody fragments. This problem can also be compensated for by linking highly potent drugs, however, this can lead to elevated risk of vascular leak syndrome (2-3).

Isolating targeting antibodies requires painstaking research to identify and produce a suitable cell surface antigen. This antigen should be uniquely expressed in the diseased tissue or at least expressed in significantly elevated levels, relative to healthy tissue. One example is HER2 − a cell surface receptor, present in approximately 15-30% of breast cancers and targeted with the ADC Trastuzumab emtansine. Once the target protein is identified and produced, a meticulous process of antibody generation and screening is required to isolate the best performing monoclonal antibodies. As these antibodies are typically isolated from rodents, ‘humanising’ the antibody is necessary to limit recognition of the ADC by the patient’s immune system and subsequent clearance from the blood stream (4).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Edward Barnes is the Laboratory Manager at Aptamer Group and has a BSc in biochemistry from the University of Leeds, UK. In his final year, Edward undertook an aptamer-based project under the guidance of Dr David Bunka, allowing him to refine his aptamer selection skills. He completed an MSc in bioscience technology at the University of York, UK. Edward has recently completed his PhD experimental work, jointly managed between Aptamer Group and the University of Manchester, UK. His thesis is now submitted and is expected to be complete by the end of the summer 2018.

Dr David Bunka is the Chief Technical Officer at Aptamer Group and holds a PhD in molecular biology from the University of Leeds, UK. He spent 12 years developing high throughput automated aptamer selection methods at the university and built up a sold international reputation in the field. Since 2003, David has isolated >300 aptamers against a wide variety of targets including: small molecule antibiotics, food contaminants, disease-associated proteins, several cancer-associated cell lines, viruses, and patient tissue samples. Since joining the group officially in 2012, David has authored several aptamer papers in peer reviewed journals, including invited review articles and a book chapter in 2012 for the Royal Society of Chemistry entitled "Therapeutic Uses of Nucleic Acid Aptamer Conjugates".

Dr Arron Tolley is the Chief Executive Officer of Aptamer Group and holds a PhD in molecular biology and biophysics from the University of Leeds, UK, and a BSc in molecular medicine. Arron has several years' experience raising aptamers against complex cellular targets and model disease systems. He has developed several aptamer panels against model cell lines associated with oesophageal adenocarcinoma. Arron still plays an active role in the R&D side of the group and is credited with the invention and development of a new aptamer based biomarker discovery platform (Aptasort) to be offered to the life sciences industry through the aptamer group.
spacer
Edward Barnes
spacer
spacer
spacer
Dr David Bunka
spacer
spacer
spacer
Dr Arron Tolley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement